DDX1 and hepatocellular carcinoma: Previous studies have shown that DDX46 could inhibit innate immunity by entrapping m6A‐demethylated antiviral transcripts in the nucleus [33], DDX5 could inhibit type I IFN production by promoting degradation of TBK1 [34], and DDX1 might be a prognostic biomarker and correlate with immune infiltrations in HCC [35].